Arthritis Treatment Reduces Painful Flare-Ups, Slows Disease
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A new therapeutic approach for rheumatoid arthritis (RA) could help prolong the time between flare-ups and even prevent the onset of the disease in at-risk patients.
This is the promise of a new study by researchers who have developed nanoparticles that both slow disease progression and reduce flare severity—rather than just manage symptoms.
RA is a chronic condition which cannot be cured that affects some 1.5 million people in the U.S. alone. It occurs when the immune system attacks joint tissue, causing inflammation, swelling and pain. As the disease progresses, more serious cartilage and bone damage can occur if not managed properly.
While disease-modifying anti-rheumatic drugs (DMARDs) like abatacept canreduce arthritis activity and slow progression of symptoms, most people still experience flare-ups. And for those with 'pre-RA', who may have detectable levels of RA antibodies but no symptoms, there aren't any approved treatments to prevent disease onset.
Older woman holding hand in pain.
Older woman holding hand in pain.The new treatment approach builds on previous research led by Dr. Nunzio Bottini, director of the Kao Autoimmunity Institute at Cedars-Sinai, and Nisarg Shah, chemical and nano engineering professor at University of California San Diego. They reported that calcitriol-loaded nanoparticles (CLNP)—calcitriol being the active form of vitamin D3—help regulate immune responses and decrease inflammation for autoimmune diseases in joints.
The nanoparticles were made of a polymer containing calcitriol, while the researchers also attached a small protein fragment to them. The fragment is derived from something called aggrecan (Agg), a protein in the joints that the immune system can mistakenly attack in RA. To expand on their previous work, the researchers set out to assess whether the modified nanoparticles could treat RA flares and pre-RA.
They first improved the nanoparticle formulation, focusing on size and stability, to ensure they were free from contaminants and could be safely frozen for a month.
They then confirmed the nanoparticles regulate dendritic cell activity, a type of immune cell responsible for initiating inflammation and flare-ups in RA.
"It is not well known what might prompt the onset of RA mainly because it is hard to get tissue from patients who do not have clear arthritis yet and we cannot predict the onset of flares to take blood or tissue right before they happen," Bottini told Newsweek.
"However, for disease onset it is believed the autoimmune attack grows over a long period of time without clinical symptoms, before emerging as clinical RA. And continuous T cell education by dendritic cells plays a role in the process.
"For flares it is believed that 'resident T cells' remain in the joints once the disease has been controlled and they can cause re-emergence of inflammation based on poorly understood fluctuations. But dendritic cells once again likely play a key role in generating/stimulating those T cells."
Doctor examining older patient's hand.
Doctor examining older patient's hand.
Chinnapong/Getty Images
The researchers took blood samples from people with and without RA and treated the samples with the newly formed Agg-CLNP (the nanoparticles with the protein). Agg-CLNP reduced dendritic cell activity which, in turn, reduced the cell's immune response, according to the researchers. By suppressing the immune response, Agg-CLNP could help alleviate RA symptoms like inflammation and swelling.
The team also tested Agg-CLNP in a mouse model for RA. It was found to delay inflammation and swelling when given as a preventative treatment, but had little effect when administered after the onset of RA.
In a follow-up, the researchers gave both the (currently used) arthritis drug abatacept and Agg-CLNP to the mice. They found that this combination delayed disease onset and reduced joint inflammation, swelling and bone damage.
Additional tests in mice also showed Agg-CLNP reduced future RA flare severity when administered after corticosteroid treatment, which is often used to provide symptomatic relief in conditions like RA, inflammatory bowel disease (IBD), asthma and more.
"There is currently no approved treatment to prevent flares so this would be the first. For disease prevention, some trials of immunosuppressive agents administered to patients at risk (as assessed by early symptoms or strong family history) have shown promising results but implementation will depend on risk-benefit considerations," said Bottini.
"We show that our nanoparticle combined with one of these agents enhances its preventative effectiveness, which might help eventually take the combination into the clinic."
These results highlight Agg-CLNP as a potential therapeutic to address current limitations in RA treatments, the researchers said.
"We think it will mainly help with preventing disease onset in patients at risk probably in combination with other immunosuppressants and to prolong the time to next flare in patients with good control of RA," Bottini explained.
"We don't know if one injection could be enough to prevent disease activity but if repeated injections [in the muscle] are needed we predict, they would occur at several months distance from each other. We are exploring whether this approach can be utilized in combination to reduce severity in patients who have active disease and not sufficient control with current therapies."
The promising therapy will need to go through optimization and toxicity studies, which can only be done in an industry setting after licensing of the technology.
"Currently, aggrecan is the antigen included in the particle. But our aspiration is that the nanoparticle is tailored based on information about the proteins that are attacked by the immune system in each individual patient as they can vary among patients," Bottini added.
"The final result would be an injectable therapy that could be personalized to each patient to maximize efficacy."
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about arthritis? Let us know via health@newsweek.com.
References
Johnson, W. T., McBride, D., Kerr, M., Nguyen, A., Zoccheddu, M., Bollmann, M., Wei, X., Jones, R. M., Wang, W., Svensson, M. N. D., Bottini, N., & Shah, N. J. (2024). Immunomodulatory Nanoparticles for Modulating Arthritis Flares. ACS Nano, 18(3), 1892–1906. https://doi.org/10.1021/acsnano.3c05298
Johnson, W. T., Wilkinson, E. L., Iyer, N., Dolmat, M., Bollmann, M., Dada, N., Wei, X., Yang, S., Zhang, T., Yoo, G., Bernardo, M., Price, M., Frame, E., Ishimori, M., Giles, J. T., Wang, W., Svensson, M. N. D., Bottini, N., & Shah, N. J. (2025). Immunomodulatory nanoparticles enable combination therapies to enhance disease prevention and flare control in rheumatoid arthritis. ACS Central Science. https://doi.org/10.1021/acscentsci.5c00723
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
19 minutes ago
- Newsweek
CHAI CEO Explains Its "Hardest" Task: Prior Auth Reform
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox. Newsweek hosted its first Women's Global Impactforum on Tuesday, and health care was a hot topic. In preparation for the forum, I got to know some incredible health care executives and dive deeper into a question I've been mulling over for ages. According to the World Health Organization, women make up nearly 70 percent of the global health care workforce. However, McKinsey & Company found that women only hold about a quarter of the industry's leadership roles and less than 20 percent of C-suite positions. How might hospitals benefit from closing the gap? Health care's stubborn "glass ceiling" has been researched for decades, yet women still haven't made substantial gains in its C-suites. And recently, workforce woes have shed new light on the issue. Frontline workers are reporting record-high levels of burnout and waning faith in management. Meanwhile, leadership teams are struggling to retain them. There's a clear disconnect between those who provide health care and those who steer health care organizations. Notably, one group is overwhelmingly female while the other is overwhelmingly male. Rhonda Jordan, executive vice president and chief human resources officer at Virtua Health, believes that balancing the scales can improve satisfaction across all levels of the organization. The New Jersey health system is a quality case study; it recently landed on Newsweek's ranking of America's Greatest Workplaces 2025 with a perfect five-star score, and it has been recognized by Press Ganey for an exceptional "culture of belonging." At the Women's Global Impact forum, Jordan shared that 60 percent of Virtua's executive leaders and 41 percent of its board members are women. That's significantly higher than the industry average and took intentional effort. "We started with a foundation, and we asked ourselves the question, 'Who did we want to be and why, and what was the culture we wanted to set?'" Jordan said. "We wanted that culture to be focused on belonging and inclusion." Virtua established a nominating committee on the board that had targets and goals around diversifying the board. Then, they inked that promise, instituting bylaws to ensure that half of the board of trustees reflects the demographics of its patient population, and more than half of its senior leaders are women. That wasn't to hit a "DEI" quota, but to get serious about succession planning and what the future of the health system should look like. Jordan and her team wanted it to represent the people they serve. Jordan and the other women on the panel—including Dr. Heather Farley (chief well-being officer at the Medical University of South Carolina, and future vice president of professional satisfaction at the American Hospital Association), Dr. Stacey Rosen (executive vice president of the Katz Institute for Women's Health at Northwell Health, and president of the American Heart Association) and Jannine Versi (co-founder and CEO of Elektra Health)—also spoke about the importance of sponsorship in raising the next generation of leaders. A mentor shares knowledge, speaking with you. But a sponsor takes the relationship to the next level by speaking about you, Jordan told the audience. "A sponsor is someone who talks about you when you're not in the room," she said. "It's that individual who is the influencer. They have to have some credibility, and they could speak to the work that you do. "Everyone should have a sponsor." Check out our live blog for more takeaways from the cross-industry event. And don't miss our Digital Health Care Forum on September 16. In Other News Major health care headlines from the week AI has solved health care's note-taking problem, but moving beyond ambient scribes—and fixing the core business—is proving to be more difficult . In my latest article for Newsweek, I spoke with leaders from Hospital for Special Surgery, MIT and more to learn how they're navigating the next phase of AI implementation. Get the scoop here. . In my latest article for Newsweek, I spoke with leaders from Hospital for Special Surgery, MIT and more to learn how they're navigating the next phase of AI implementation. Get the scoop here. In 2017, only three urban hospitals dually qualified as rural hospitals. By 2023, there were 425 hospitals with that designation , per a new study published in Health Affairs. , per a new study published in Health Affairs. That's thanks to a 2016 CMS rule which allows hospitals to use urban wage indexes to calculate Medicare reimbursements—while simultaneously benefiting from programs reserved for rural hospitals, like easier eligibility for 340B. "Congress should ensure that federal programs supporting rural health are directed solely to geographically rural hospitals," argued the report's authors from Brown University and Johns Hopkins University. However, such changes would likely prompt pushback from hospitals that are based in urban epicenters yet treat a significant rural population. argued the report's authors from Brown University and Johns Hopkins University. However, such changes would likely prompt pushback from hospitals that are based in urban epicenters yet treat a significant rural population. Outcomes are improving for hospital surgical patients , according to a new report from the American Hospital Association (AHA) and Vizient. The new analysis builds on findings from last fall that hospitalized patients were nearly 20 percent more likely to survive than expected in the first quarter of 2024 than in the fourth quarter of 2019, based on their acuity. , according to a new report from the American Hospital Association (AHA) and Vizient. The new analysis builds on findings from last fall that hospitalized patients were nearly in the first quarter of 2024 than in the fourth quarter of 2019, based on their acuity. This week's report attributed that win to declining rates of falls and hospital-acquired infections, plus fewer instances of post-operative conditions like hemorrhage, sepsis and respiratory failure . . Still, as care shifts to the outpatient and ambulatory setting, hospitals are likely to see higher-acuity patients over the next decade. The AHA and Vizient found that the average length of stay for hospitalized surgical patients has increased by about one full day over the past five years. over the past five years. Secretary Robert F. Kennedy Jr. and the Department of Health and Human Services (HHS) have rolled back more federal policies that incentivized hospitals to report staff vaccination rates . . The move will decouple hospitals' reimbursement rates from staff vaccination rates, which is sure to eliminate some of the reporting burden on health systems. But it also raises questions about hospitals' responsibilities to public health as vaccination rates decline across the nation, while diseases like measles, whooping cough and hand, foot and mouth disease are back on the rise. Pulse Check Executive perspectives on key industry issues Dr. Brian Anderson is the president and CEO of the Coalition for Health AI, known as CHAI. Dr. Brian Anderson is the president and CEO of the Coalition for Health AI, known as CHAI. CHAI When I want a well-rounded perspective on the health care industry, Dr. Brian Anderson is my first call. He's the president and CEO of the Coalition for Health AI (CHAI), which brings together more than 3,000 organizations from across the industry to develop best practices for health care AI. He works closely with technology developers, government officials, patient advocates, payers and providers to find solutions that all parties can get behind. On Monday, I spoke with Anderson about CHAI's working group that focuses on prior authorization reform. The goal is to get payers and provider groups "on the same page," he told me. That's easier said than done. But it's necessary work, and a priority of the federal government, too. CMS is also working to automate prior authorization through its WISeR model, which aims to leverage technology and expedite the claims process for certain conditions. Below, find a portion of my interview with Anderson about prior authorization automation—and aligning stakeholders on a common goal. Editor's Note: Responses have been lightly edited for length and clarity. Brian, you've said that payers and providers need to align on the technical aspects of a best-practice framework for digitally driven prior auth reform. What do providers want to include in that framework? One of the more common areas of agreement with the provider groups is the minimum amount of data that's needed to make the decision. I think many patients would agree with that, right? Like, I don't necessarily want my data to be shared openly with everyone if that data is not going to be used for a specific purpose. And I think that's part of the challenge. If the payers need a certain amount of data to make a decision, and the providers are willing to give that data, what is the minimum amount of data that's needed that we can share as quickly as possible—ideally electronically—in such a way that that decision can be made accurately and quickly for the patient? It's obvious, but worth stating, [that] sharing that data electronically versus on a paper form that's filled out and then faxed over [would be faster]. So creating the kinds of preauthorization pathways that allow data to flow in a more automated fashion, leveraging things like the technical framework or some of these CMS Aligned Networks , that, of course, requires a level of interoperability between providers and payers that would be beneficial to both sides. In July, you spoke on a panel at CMS' Quality Conference. During that discussion, the moderator, CMS Administrator Dr. Mehmet Oz, mentioned that 49 percent of doctors are still responding to prior auth requests on paper. How can technology be used to reduce that number? Yeah, [there are] a number of things. In a pre-AI world, if you wanted to digitally map each field of a preauthorization form to specific elements within the EHR, that's a hand-crank manual process of mapping to extract those data elements and be able to fill out a form electronically. In an AI-driven world, if you're training a model to be able to understand the kinds of data and the intent of what that specific field in that form is trying to get, you can then train a model to look for those specific data elements in the EHR. The heart of all this is going to be, can we have AI models that are trained in an appropriate way to look at an EHR record and extract the minimum amount of data needed for that pre-authorization form? AI can be trained in in a way that doesn't require the kind of hard coding of "field X here, field 1 here, field Y here." These models can be trained to look for that kind of data or to summarize a particular field in the preauthorization form that might come from several different parts of an EHR. That kind of summarization, or that kind of intent, is something that you can train these models on, particularly in the generative AI space. And in doing that, you're reducing the burden significantly on a provider or a nurse. Oftentimes other people have to fill out these forms, and it takes time, and it's on paper. So, the hope is that, one, it's digitized. Two, it's automated. Three, it's automated in such a way that you can get these kinds of communications as close to real time as possible. You've been a part of a number of these conversations at a national level and work with thousands of organizations across the ecosystem. What is the sentiment about this sort of reform right now? Is there excitement, skepticism? How are people feeling? I'd say there's probably more skepticism than excitement. This is a really hard space. It's probably one of the hardest, if not the hardest working group that we have, because of the lack of trust and the stakes. But that's why it's so important. And I mean, this is something that our community has asked us to try to focus on, so we're going to try our best. I think it's important to remember that these documents are living documents, and so developing a best practice doesn't mean that we've developed it and we can move on to something else entirely. This is the beginning of a journey, and hopefully building the kind of common language and frameworks that both parties can agree to will ultimately get us to a level of trust. Will we get there in six months? If I'm being honest, I don't know. Chances are we might not. I'd be pleasantly surprised if we did. I think the stakes are pretty high. And we're hearing from patients pretty clearly that they want this solved. The administration has made that clear too, and so this is absolutely a priority for us. C-Suite Shuffles Where health care leaders are coming and going Intermountain Health is switching up its pediatric leadership ahead of Katy Welkie's planned retirement in late August. Welkie is currently the CEO of Intermountain Primary Children's Hospital in Salt Lake City and vice president of children's health for the system. Dustin Lipson , president of Intermountain Primary Children's Hospital, will assume an expanded role overseeing pediatric care throughout southwest Idaho and central Utah. Mandy Richards —Intermountain's chief nurse executive—will take the reins from Lipson to become president of Intermountain Primary Children's Hospital. Highmark Health, based in Pittsburgh, has tapped Dr. Alistair Erskine as its chief information digital officer. He joins the payer-provider enterprise from Emory Healthcare and University in Atlanta, where he managed a $350 million annual budget as senior vice president, chief information officer and chief digital officer. He also established a chief financial informatics officer role at Emory and was instrumental in creating the world's first hospital that is fully powered by Apple products. Susan Monarez as director of the Centers for Disease Control and Prevention (CDC) last Thursday. In case you missed it, Robert F. Kennedy Jr. swore in last Thursday. Monarez previously served as acting director of CDC and deputy director for the Advanced Research Projects Agency for Health, working on disease detection, treatment technologies and data collection. According to NPR, she is the first CDC director to be confirmed by the Senate and the first to hold the title without a medical degree in more than seven decades. She received her PhD in microbiology and immunology from the University of Wisconsin-Madison. Executive Edge How health care execs are managing their own health Dr. Jessica Shepherd is the chief medical officer at Hers. Dr. Jessica Shepherd is the chief medical officer at Hers. Hers Hers blessed us twice at Tuesday's Women's Global Impact forum, with (1.) a sponsored cocktail hour and (2.) their Chief Medical Officer Dr. Jessica Shepherd. Shepherd joined Newsweek's Kylie McCoy for a fireside chat, sharing personal stories and professional insights on improving access to women's health care. The conversation covered innovations in telehealth, drug compounding and personalized care. But for today's Executive Edge, I pulled a few of her insights on self-awareness and advocacy. I think they'll prove useful for anyone who is working to care for themselves while pouring out for others. Editor's Note: Responses have been lightly edited for length and clarity. " wink, if you know what I'm talking about. Even as a physician, going through it myself right now, it's [about] my favorite word, self-awareness." "I would [suggest] for everyone who's in midlife to say, "Let me do a pause and take a stop right here and reflect on myself. What do I need in this moment, and how am I going to get that?" Being the chief medical officer, that's one of the biggest emphases that I can have. How do I care for women in a way that is going to make them more self-aware and advocate for themselves? Being the chief medical officer, that's one of the biggest emphases that I can have. How do I care for women in a way that is going to make them more self-aware and advocate for themselves? "I think the best advice that I've been given is always believe in yourself. You are going to be that best vehicle that's going to get you to the place that you want to go within yourself. If I were to talk to my 30-year-old self, I would say, believe in yourself, but also never fear the outcome. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Newsweek
2 hours ago
- Newsweek
With Eyes on 2028, Democratic Governors Rip Page From Trump Playbook
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Three of the Democratic Party's highest-profile governors—California's Gavin Newsom, Illinois' JB Pritzker and Minnesota's Tim Walz—are taking a page from President Donald Trump's playbook by rolling back public health care for undocumented immigrants. All three governors have greenlit proposals to freeze, cap or eliminate health benefits for noncitizens without legal status, citing budget shortfalls. The policy reversals, which will impact tens of thousands of people in some of the country's most immigrant-heavy states, come as each leader is widely viewed as a potential contender for the Democratic presidential nomination in 2028. In Illinois, a program that provided publicly funded health coverage to over 30,000 undocumented adults ended July 1. Governor JB Pritzker included the cut in his latest state budget, telling it was a "difficult decision" forced by national economic headwinds. "This year, passing a balanced budget required the difficult decision that reflects the reality of Trump and Republicans tanking our national economy and attempting to strip away healthcare," Pritzker's office told Newsweek, referencing prior comments made by the governor. Illinois Governor JB Pritzker, California Governor Gavin Newsom, and Minnesota Governor Tim Walz have each backed cuts to health care programs for undocumented immigrants, drawing criticism from progressive groups and immigrant advocates. Illinois Governor JB Pritzker, California Governor Gavin Newsom, and Minnesota Governor Tim Walz have each backed cuts to health care programs for undocumented immigrants, drawing criticism from progressive groups and immigrant advocates. Getty Images Eliminating the program for middle-aged adults is projected to save the general revenue fund about $330 million, according to the governor's office. Minnesota followed shortly after. A bipartisan bill passed by the legislature and signed by Governor Tim Walz removed undocumented adults from MinnesotaCare, the state-run insurance program for low-income residents. "No one got everything they wanted," Walz said after the compromise was finalized in a special session. "There were very difficult conversations... but at the end of the day, we were able to come to this agreement". California Governor Gavin Newsom, who has frequently spoken about health equity, unveiled a plan in May to cap new enrollment for undocumented adults in Medi-Cal, the state's Medicaid program. While those currently enrolled will not lose coverage, they will face new costs—including a $100 monthly premium starting in 2027—and cuts to dental services. "We are not cutting or rolling back those that are already enrolled in our Medi-Cal system, we're just capping it," Newsom said on July. "No state has done more than the state of California... That's a point of pride". More than 120 organizations signed an open letter condemning Newsom's Medi-Cal cuts, calling them more harmful than the health care changes included in Trump's "big, beautiful" tax and spending bill. 'Not Just Tone' Newsom, Pritzker, and Walz are widely seen as potential candidates for the 2028 Democratic presidential nomination. A Morning Consult poll from April showed Newsom with 11 percent support among Democratic primary voters, tied with Pete Buttigieg and behind only Kamala Harris. An Echelon Insights poll also showed Newsom at 6 percent, Pritzker at 2 percent, and Walz around 3 percent. All three have increased their national visibility, with Newsom and Pritzker making appearances in early primary states. But critics say the three Democrats are courting political optics at the expense of vulnerable residents. President Donald Trump arrives to speak at Fort Bragg, Tuesday, June 10, 2025, in Fort Bragg, N.C. President Donald Trump arrives to speak at Fort Bragg, Tuesday, June 10, 2025, in Fort Bragg, N.C. Associated Press "These governors may be known for their sharp anti-Trump rhetoric, but their recent policy choices echo the very worst aspects of his administration: using immigrants—particularly those without the right to vote—as economic scapegoats," wrote Jim Mangia, president of St. John's Community Health, in a column for The Hill. Public health experts have long argued that covering undocumented residents reduces costs by avoiding more expensive emergency room visits and stabilizing community health care systems. Mangia cited a University of Chicago study showing state-run immigrant coverage had created cost savings for Illinois hospitals. Immigrant rights organizations have condemned the changes. "Terminating state coverage for immigrants will compromise our collective health, as well as the health care infrastructure that serves all of us," Tanya Broder, senior counsel at the National Immigration Law Center, told NBC News. Progressive groups have warned the cuts risk alienating the Democratic base. "This assumption that by moving more to the middle or to the right that you're going to recruit some people back—I think it's a miscalculation," Jennifer Driver of State Innovation Exchange told NBC. "The frustration that you're seeing in the Democratic base is due to this kind of waffling". Meanwhile, Republicans have seized on the reversals. In Colorado, GOP members of Congress have called on Democratic Governor Jared Polis to roll back health care programs for undocumented residents, citing the actions in California, Minnesota and Illinois. "Every dollar that Colorado hands out for free health care for illegal immigrants is money that can't be spent on seniors and rural hospitals," a spokesperson for Republican Rep. Gabe Evans told Newsweek. For now, Newsom, Pritzker and Walz say they are juggling competing priorities while trying to balance their budgets. But immigrant advocates warn the damage could be lasting—both for vulnerable residents and for Democrats trying to distinguish themselves from Trump on policy, not just tone. "These cuts are not just cruel—they are economically shortsighted," Mangia wrote. "We need leaders who will fight to expand care—not slash it".
Newsweek
2 hours ago
- Newsweek
Drug Could Stop Life-Threatening Food Allergies in Millions
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A drug used for asthma has been found to treat food allergies "shockingly well", in a breakthrough that could offer new protection for millions affected. This is the discovery of Northwestern Medicine scientists, who have revealed the already FDA-approved drug nearly eliminated life-threatening allergic reactions to food allergens in mice. Around 33 million people in the U.S. have at least one food allergy—that is nearly one in 10 adults and one in 13 children. While just over half of all adults and 42 percent of children with food allergies have experienced a severe reaction, predicting an individual's risk of this happening and preventing it remains challenging. Currently, the only two FDA-approved treatments for certain food allergies are an oral immunotherapy for peanut allergy (which doesn't work for everyone and can itself trigger anaphylaxis, according to the researchers) and an expensive injection called omalizumab (which also isn't effective for everyone.) Woman pouring peanuts in measuring bowl. Woman pouring peanuts in measuring bowl. CarolinaWhile anaphylaxis is currently primarily treated with epinephrine (adrenaline), it's hoped the asthma drug called Zileuton could offer a simple pill that temporarily shields allergic individuals by blocking the body's anaphylactic pathway before it activates. "It was actually shocking how well Zileuton worked," said Dr. Stephanie Eisenbarth, study author and Allergy and Immunology chief at Northwestern's Feinberg School of Medicine, in a statement. "After treatment with Zileuton, 95 percent of the mice showed almost no symptoms of anaphylaxis. The treatment reversed their risk from 95 percent susceptible to 95 percent protected," added Adam Williams, study author and allergy and immunology professor at Feinberg, in a statement. The revelation came after the researchers identified, in mice, a previously unknown role for a gene called DPEP1, which they found was essential in regulating anaphylaxis, a potentially fatal and rapid allergic reaction. By using Zileuton to block the pathway involving this gene, the scientists nearly eliminated allergic responses in mice that were previously highly susceptible to food-induced anaphylaxis. The mice were given peanut extract orally—peanuts being the most common cause of anaphylaxis due to food in people—shortly after receiving Zileuton. "For the past decade we have been working to understand why some people with a positive blood test for a food allergy have no symptoms when they eat that allergen, whereas others have severe allergic reactions (anaphylaxis)," Eisenbarth and Williams told Newsweek. "The goal is to find ways to make people with symptomatic food allergy tolerate exposure to allergens. We had many theories about what could provide this form of protection but none could explain it. "So, we turned to an unbiased approach to potentially discover unexpected pathways. Through a genetic screen we found DPEP1 and the leukotriene pathway." Man holding a pill in his hand. Man holding a pill in his newly identified pathway followed a 'forward genetic screen' lasting a year, a research method where scientists breed generations of mice to determine the specific genes responsible for biological differences like susceptibility to food allergy. Once they found the DPEP1 gene controlled inflammatory molecules called leukotrienes in the gut (inflammatory molecules already targeted by asthma drugs), they tested Zileuton, which blocks their production. "The idea that absorption of intact allergens is constantly regulated in the gut by this leukotriene pathway is completely unexpected," said Eisenbarth and Williams. They hope their findings pave the way for better preventative methods, rather than treating the symptom. "The idea is to take a single dose right before a potential exposure to prevent anaphylaxis, rather than a drug (e.g., epi-pen) to treat a reaction after it has started. We see this especially valuable in 'high risk' situations in which accidental allergen exposures are more likely, such as getting on a flight, going to a restaurant, or a child attending a birthday party," the study authors explained. "It is important to emphasize that so far, we only have data from mouse models. Our current clinical trial [which started last month] will test whether this could also work in humans. Because we do not know how continuous treatment would affect the gut or the immune system, we are not considering this a daily treatment." The researchers said that they didn't observe any side effects in the mouse study. They added: "Rarely in people, this drug has induced changes in liver function tests when taken continuously, but we only give one single dose, and therefore such reactions would be unlikely." "This is a totally different, out-of-the-box approach to treat food allergy, unlike anything we've tried before," Williams noted. Current diagnostic tests only estimate allergy risk, not tolerance. While the researchers believe some people are naturally protected, this is also an area for further research. "The clinical trial is the first step in testing whether we can block food allergen absorption in people through the same pathways. If the answer is yes, the next step would be to test whether people with food allergy are protected from anaphylaxis," the researchers concluded. "But there are a lot of other exciting questions, like whether this pathway is regulated by things in our environment such as changes in the microbiome induced by diet." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about food allergies? Let us know via health@ Reference Hoyt, L. R., Liu, E., Olson, E. C., Jacobsen, D. R., Siniscalco, E. R., Krier-Burris, R. A., Greenfield, K. G., McBride, C. D., Alfajaro, M. M., Amat, J. A. R., Zhao, Z., Xu, L., Philip, V., Verma, A., Fourati, S., Senger, D. L., Zhang, L., Bunyavanich, S., Glass, S. E., Coffey, R. J., Wilen, C. B., Williams, A., & Eisenbarth, S. C. (2025). Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice. Science, 389(6656).
